Welcome to BioSeeker Group!

Triple Analysis: Prostate Cancer, Cancer Vaccines and Protein Kinase Inhibitors

Additional Information

Published Date Mar 19, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 5440
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Prostate Cancer, Cancer Vaccines and Protein Kinase Inhibitors in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in Prostate Cancer and by the two mechanism/target/effect areas of Cancer Vaccines and Protein Kinase Inhibitors.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Prostate Cancer, Cancer Vaccines and Protein Kinase Inhibitors.

    To find out more about Triple Analysis: Prostate Cancer, Cancer Vaccines and Protein Kinase Inhibitors, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Prostate Cancer, Cancer Vaccines and Protein Kinase Inhibitors is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in Prostate Cancer and by the two mechanism/target/effect areas of Cancer Vaccines and Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Prostate Cancer
The prostate cancer drug report part comprises defined and up to date development strategies for 394 drugs within the portfolio of 222 companies world-wide, from Ceased to Marketed. The report extensively analyses their 227 identified drug targets, organized into 216 drug target strategies, and assesses them in breast cancer drug development.
This part is based on the following publication:
Competitive Handbook towards Personalized Medicine in Prostate Cancer

Part II: Cancer Vaccines
The cancer vaccine drug report part comprises defined and up to date development strategies for 196 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 137 identified drug targets, organized into 114 drug target strategies, and assesses them in 52 cancer indications.
This part is based on the following publication:
Cancer Vaccines: From First-in-Class to Best-in-Class?

Part III: Protein Kinase Inhibitors
The protein kinase drug report part comprises defined and up to date development strategies for 648 drugs in oncology within the portfolio of 212 companies world-wide, from Ceased to Marketed. The report extensively analyses their 183 identified drug targets, organized into 278 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Competitive Insights to Protein Kinase Therapeutics in Oncology: The Faster Route to Consider Your Options and Position of Others

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Prostate Cancer
5.1 The Scope of this Report 31
6 Consider the Therapeutic Target Among Prostate Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (227 Drug Targets) 35-437
7 Emerging New Products to Established Ones: Drug Target Strategies of Prostate Cancer Drugs by their Highest Stage of Development (216 Drug Target Strategies and 394 Drugs) 438-699
8 Compound Strategies at Work: Competitive Benchmarking of Prostate Cancer Drugs by Compound Strategy (8 Compound Strategies) 700-748
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Prostate Cancer Drug Pipeline by Investigator (222 Investigators and 394 Drugs) 749-1470
10 Disclaimer 1471
Figures: Includes 8 Figures
Tables: Includes 283 Tables
Total Number of Pages: 1,493

Part II: Cancer Vaccines
5.1 The Scope of this Report 28
6 Consider the Therapeutic Target Among Cancer Vaccine Drugs for the Highest Therapeutic Outcome and Return on Investment (137 Drug Targets) 32-245
7 First-in-Class and Me-too Analysis of Cancer Vaccine Drugs (114 Drug Target Strategies and 196 Drugs) 246-262
8 Is First-in-Class the Best-in-Class? 263-386
9 Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine Drugs by Compound Strategy (7 Compound Strategies) 387-413
10 The Competition Through Close Mechanistic Approximation of Cancer Vaccine Drugs 414-416
11 Selecting Indications for Cancer Vaccine Drugs (52 Cancer Indications) 417-492
12 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Vaccine Drug Pipeline by Company (114 Companies and 196 Drugs) 493-993
13 Disclaimer 994
Figures: Includes 5 Figures
Tables: Includes 239 Tables
Total Number of Pages: 1,007

Part III: Protein Kinase Inhibitors
5.1 The Scope of this Report 38
6 Consider the Therapeutic Target Among Protein Kinase Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (183 Drug Targets) 42-516
7 Emerging New Products to Established Ones: Drug Target Strategies of Protein Kinase Drugs in Oncology by their Highest Stage of Development (278 Drug Target Strategies and 648 Drugs) 517-945
8 Compound Strategies at Work: Competitive Benchmarking of Protein Kinase Cancer Drugs by Compound Strategy (8 Compound Strategies) 946-1013
9 Selecting Indication for Protein Kinase Drugs in Oncology (70 Cancer Indications) 1014-1223
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Protein Kinase Drug Pipeline in Oncology by Investigator (212 Investigators and 648 Drugs) 1224-2939
11 Disclaimer 2940
Figures: Includes 8 Figures
Tables: Includes 389 Tables
Total Number of Pages: 2,940

This Report Includes the Following Companies:
4SC
AB Science
Abbott
Abiogen
AC Immune
Acceleron Pharma
ACT Biotech
Active Biotech
Adaptimmune
Advantagene
Advaxis
Advenchen
AEgera
AEterna Zentaris
Agenus
Aida Pharmaceuticals
Alchemia
Alethia Biotherapeutics
Allist Pharmaceuticals
Allos Therapeutics
Allostera
AlphaVax
Alseres Pharmaceuticals
Altor BioScience
Ambit Biosciences
Ambrilia Biopharma
American Gene Technology International
Amgen
Amphora
Anavex Life Sciences
AndroBioSys
Ansaris
Antisense Pharma
Antisense Therapeutics
Antisoma
Anza Therapeutics
Aphios
Apogee Biotechnology
ApopLogic Pharmaceuticals
Apotex
Aprea
Ardana
Argos Therapeutics
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Ascenta Therapeutics
Ascepion Pharmaceuticals
Astellas
Astex Pharmaceuticals
AstraZeneca
Attenuon
AVI BioPharma
Avila Therapeutics
Bavarian Nordic
Baxter International
Bayer
Bellicum Pharmaceuticals
Benitec
Berkeley Lab
Bio-Path Holdings
BioAxone
Bioenvision
Biogen Idec
BioLineRx
BioMarin
BioNetWorks
Bionovo
BioNTech
BioSante
Biostar
Biotecnol
Biotica Technology
BioVex
Boehringer Ingelheim
BreakThrough Therapeutics
Bristol-Myers Squibb
BTG
Callisto Pharmaceuticals
Cambrex
Camurus
CanBas
Cancer Advances
Cancer Research Technology
Catalyst Biosciences
Cel-Sci
Celgene
Cell Therapeutics
CellCeutix
Celldex Therapeutics
Celleron
Celsion
Center of Molecular Immunology
Cephalon
CerRx
CG Therapeutics
Chemokine Therapeutics
Chroma Therapeutics
Circadian Technologies
Cleveland BioLabs
Clinical Data
Colby
CompleGen
Compugen
CoNCERT Pharmaceuticals
Cosmo Bioscience
Cosmo Pharmaceuticals
CreaGene
CSL
Curaxis
CureVac
Curis
Cyclacel
Cylene Pharmaceuticals
Cytokine PharmaSciences
Cytokinetics
Cytopia
Daiichi Sankyo
Dainippon Sumitomo Pharma
Debiopharm
Deciphera Pharmaceuticals
Dendreon
DeveloGen
DiaMedica
Dongkook Pharm
Dyax
ECI
Eisai
Elara Pharmaceuticals
Eli Lilly
Endo Pharmaceuticals
Endocyte
Enkam Pharmaceuticals
Ensemble Discovery
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Erimos
Esperance Pharmaceuticals
Etubics
EUSA Pharma
Exelixis
Ferring
Formula Pharmaceuticals
Galapagos
Galena Biopharma
Gemin X Pharmaceuticals
Generex
GenOdyssee Pharmaceuticals
GENova Biotherapeutics
Genovax
Genta
Genticel
Gerolymatos
Geron
Gilead Sciences
GlaxoSmithKline
Gliknik
GlobeImmune
GlycoGenesys
Got-a-Gene
GP Pharm
GPC Biotech
Gradalis
Green Cross
GTx
Hanmi
Harbor BioSciences
Heat Biologics
Hemispherx Biopharma
Hoffmann-La Roche
Human Genome Sciences
Hutchison China MediTech
Hypha Discovery
Ichor Medical Systems
Idera Pharmaceuticals
IGF Oncology
ImClone Systems
immatics biotechnologies
ImmunoCellular Therapeutics
Immunocore
ImmunoFrontier
ImmunoGen
Immunomedics
Immunotope
Immunovaccine
ImmuPharma
Incozen Therapeutics
Incyte Corporation
Infinity Pharmaceuticals
Inhibiton Therapeutics
Inovio
Insmed
Insys Therapeutics
Intellikine
Intracel
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
ISU ABXIS
Ivy Medical Chemicals
Jennerex Biotherapeutics
Jina Pharmaceuticals
Johnson & Johnson
Kadmon
KAEL-GemVax
KAI Pharmaceuticals
KaloBios
Kalypsys
Karo Bio
Karus Therapeutics
Keryx Biopharmaceuticals
Kiadis
Kinex
Kirin Pharma
KuDOS
Kyowa Hakko Kirin
Leo
Lexicon Pharmaceuticals
Ligand
Lipotek
Lorus Therapeutics
Mannkind
Marillion Pharmaceuticals
Marina Biotech
MaxoCore Pharmaceuticals
Med Discovery
Meda
Medarex
MediGene
MedImmune
Mediolanum
Medisyn Technologies
Medivation
Menarini
Merck & Co
Merck KGaA
Merrimack
Merrion Pharmaceuticals
MethylGene
Micromet
Mitsubishi Tanabe Pharma
Mojave Therapeutics
Molecular Insight
Molecular LogiX
MolMed
Mologen
Momotaro-Gene
Myrexis
Nano Terra
Nektar Therapeutics
Nemod Biotherapeutics
Neovacs
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neurocrine Biosciences
NexusPharma
NicOx
Nidus Laboratories
NIH
Nippon Shinyaku
Non-industrial source
Northwest Biotherapeutics
Novacea
NovaLead
Novartis
NovaRx
Novogen
Oasmia
Oncalis
OncoGenex Pharmaceuticals
OncoMune
Onconova
OncoTherapy Science
Oncothyreon
Oncovir
Onyvax
Orchestra Therapeutics
Orion Pharma
OSI Pharmaceuticals
Oxford BioMedica
Paladin Labs
Pantarhei Bioscience
Pathway Therapeutics
Pepscan Therapeutics
Peptagen
Peregrine Pharmaceuticals
Pfizer
Pharmacyclics
PharmaForm
PharmaGap
PharmaMar
Pharmexa
Philogen
Phoenix Biotechnology
PHusis Therapeutics
Pieris
Pierre Fabre
Piramal
PIramed
Portola Pharmaceuticals
Proacta
Progen
Progenics Pharmaceuticals
ProNAi Therapeutics
ProStrakan
Protherics
Provid
Q Chip
QLT
Quantum Pharmaceuticals
Radient Pharmaceuticals
Ras Therapeutics
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
responsif
Rexahn
Rigel
Salzburg Therapeutics
Samtheo Biopharma
Samyang
Sanofi
Santaris Pharma
Sapphire Therapeutics
Sarepta Therapeutics
Sareum
SBI Biotech
SBIO
Scancell
Schering-Plough
SeleXel
Selvita
Semafore Pharmaceuticals
Sentinel Oncology
Serometrix
SGX Pharmaceuticals
Shionogi
Shire
Siena Biotech
Silence Therapeutics
Soligenix
Sophiris Bio
SRI International
Sunesis
Supratek Pharma
Swedish Orphan Biovitrum
Switch Pharma
Symphogen
Synta Pharmaceuticals
Taiho
Takeda
Tamir Biotechnology
Tapestry Pharmaceuticals
TapImmune
Targa Therapeutics
TargeGen
Tau Therapeutics
TauTaTis
TCD Pharma
Tekmira Pharmaceuticals
Telik
Teva
Thallion Pharmaceuticals
Therion Biologics
Theryte
Tigris Pharmaceuticals
Titan Pharmaceuticals
Tokai Pharmaceuticals
ToolGen
TopoTarget
Tracon Pharmaceuticals
Tragara Pharmaceuticals
Transgene
TransTech Pharma
Twinstrand Therapeutics
UCB
Unigene
United Biomedical
Vaccinex
VasGene Therapeutics
Vaxil BioTherapeutics
Vaximm
Vaxon Biotech
Vectura
Velacor Therapeutics
Vernalis
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest
Viragen
Viralytics
Virionics
ViroMed
ViroTarg
VM Discovery
Wyeth
Xcovery
Xencor
Xerion
Xoma
YM BioSciences
Zensun
Zenyaku Kogyo
Zydus Cadila
A Shortlist of Drugs Included are:
abagovomab
abarelix
abiraterone acetate
AC-480
adecatumumab
aderbasib
ADXS11-001
AE-37
AEZS-108
AF-802
afatinib
aflibercept
AGS-003
ALT-801
alvocidib
AMG-386
amonafide dihydrochloride
amonafide malate
Angiozyme
ANZ-207
apatinib
APC-100
APR-246
AR-42
ARC-100
ARQ-197
astuprotimut-r
AT-7519
AT-9283
atrasentan
Auto TAG vaccine
AVX-701
axitinib
AZD-8055
AZD-8931
bafetinib
barasertib
bardoxolone methyl
belagenpumatucel-L
bevacizumab
BEZ-235
BGT-226
BI-811283
BIBF-1120
bicalutamide
BMS-690514
BMS-754807
BMS-777607
BMS-936558
bortezomib
bosutinib
BP-GMAX-CD1
brivanib alaninate
buserelin
BV-NSCLC-001
Cabozantinib
CAL-101
carlumab
CB-10-01
CBP-501
CC-223
CDX-1307
cediranib
celecoxib
cetuximab
CG-201
cixutumumab
CreaVax-PC
crizotinib
custirsen
CV-9103
CV-9201
CVac
dacomitinib
danusertib
dasatinib
DCVax-prostate
degarelix
denosumab
deslorelin
DI-17E6
dinaciclib
docetaxel
dovitinib lactate
doxercalciferol
doxorubicin
dutasteride
E-75
emepepimut-S
endoxifen
ENMD-2076
entinostat
enzastaurin hydrochloride
erlotinib
estramustine phosphate sodium
ethinyl estradiol sulfonate
everolimus
figitumumab
flutamide
foretinib
fostamatinib disodium
fulvestrant
gataparsen
GDC-0980
gefitinib
GI-4000
goserelin
GSK-2118436
GSK-2130579A
GTx-758
GV-1001
GVAX
GVX-3322
GX-301
HE-3235
Her-2/Neu peptides
Hi-8 MEL
histrelin
HS-110
IC-83
icrucumab
ICT-107
idronoxil
imatinib mesilate
imMucin
IMO-2055
INCB-028060
inecalcitol
INSM-18
interleukin-12
interleukins
intetumumab
ipilimumab
irosustat
ISA-P53-01
ispinesib mesylate
JI-101
JX-594
KD032
KX2-391
lapatinib ditosylate
lenvatinib
lestaurtinib
leucine-doxorubicin
leuprolide
leuprolide acetate
leuprorelin
leuprorelin acetate
linifanib
linsitinib
LIP-131I
LipoVIL12
litronesib
LOR-2040
LOR-2501
LY-2090314
LY-2275796
masitinib
MCS-110
MDV-3100
MDX-1379
MGCD-265
MGN-1601
midostaurin
MK-1775
MKC-1
MLN-8237
MM-111
motesanib diphosphate
MVA-BN Her-2 vaccine
Nab-docetaxel
nadroparin
neratinib
nilotinib
nilutamide
nimotuzumab
NPB-001-056
oblimersen sodium
OGX-427
olaparib
olaratumab
ON-01910
onartuzumab
OncoVAX
Onyvax-105
orteronel
OSI-027
OTS-102
ozarelix
p.DOM-WT1-37/p.DOM-WT1-126 DNA
P276-00
paclitaxel
paclitaxel polyglumex
panitumumab
panobinostat
pazopanib hydrochloride
PD-0332991
pegdinetanib
perifosine
pertuzumab
PHA-848125AC
plitidepsin
PLX-3397
poly-ICLC
polyclonal antibody stimulator
ponatinib
ProstAtak
PROSTVAC
PRX-302
PSMA ADC
PX-866
quarfloxacin
quinacrine
quizartinib dihydrochloride
R-(-)-gossypol
RAF-265
ramucirumab
regorafenib
retaspimycin
Reximmune-C
ridaforolimus
rilotumumab
rindopepimut
rintatolimod
romidepsin
ruxolitinib
RX-0201-N
S-488410
sagopilone
sargramostim
SB-939
SCH-900776
SCIB-1
seliciclib
siltuximab
sipuleucel-T
sirolimus
sorafenib tosylate
ß-lapachone
SU-6668
sunitinib malate
Survivac
TAK-448
talmapimod
tandutinib
tasquinimod
telatinib
temsirolimus
Tenarad
terameprocol
TG-4010
thymalfasin
tipapkinogene sovacivec
tivozanib
TOK-001
toremifene citrate
TRC-105
tremelimumab
triciribine phosphate
trilostane
triptorelin
TroVax
TS-1
tucotuzumab celmoleukin
vandetanib
varlitinib
velimogene aliplasmid
vemurafenib
verpasep caltespen
vitespen
volasertib
vosaroxin
VX-001
XL-147
XL-281
XL-413
XL-647
XL-765
YM-155
zibotentan

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Prostate Cancer, Cancer Vaccines and Protein Kinase Inhibitors.
    To find out more about Triple Analysis: Prostate Cancer, Cancer Vaccines and Protein Kinase Inhibitors, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Prostate Cancer, Cancer Vaccines and Protein Kinase Inhibitors is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Lung Cancer, Angiogenesis and Peptides
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lung Cancer), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Peptides). Learn More


Triple Analysis: Breast Cancer, Lymphoma and Antibodies
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Lymphoma and by the compound strategy of Antibodies. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Apoptosis, Angiogenesis and Peptides
This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Apoptosis and Angiogenesis and by the compound strategy of Peptides. Learn More


Triple Analysis: Lung Cancer, Melanoma and Cancer Vaccines
This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Melanoma and by the mechanism/target/effect of Cancer Vaccines. Learn More